Undue Computational Experimentation: Can In Silico Experiments Allows Genus Claims to Survive?
U.S. courts have, time and again, struck down genus claims for undue experimentation. The most recent blow came last year in Amgen v. Sanofi, when the Supreme Court affirmed the lower court’s ruling that Amgen’s patent on antibodies with a specific target was invalid for lack of enablement. In that ruling, the Court invoked the...
U.S. courts have, time and again, struck down genus claims for undue experimentation. The most recent blow came last year in Amgen v. Sanofi, when the Supreme Court affirmed the lower court’s ruling that Amgen’s patent on antibodies with a specific target was invalid for lack of enablement. In that ruling, the Court invoked the...
Executive Summary
The article discusses the validity of genus claims in light of the Supreme Court's ruling in Amgen v. Sanofi, which affirmed the lower court's decision that Amgen's patent on antibodies with a specific target was invalid due to lack of enablement. The article explores whether in silico experiments can help genus claims survive despite the Court's emphasis on undue experimentation. The ruling has significant implications for patent law, particularly in the biotechnology sector, where genus claims are common. The article analyzes the potential impact of in silico experiments on the validity of genus claims and the future of patent law.
Key Points
- ▸ The Supreme Court's ruling in Amgen v. Sanofi has significant implications for genus claims
- ▸ In silico experiments may be used to support genus claims
- ▸ The Court's emphasis on undue experimentation poses challenges for patent holders
Merits
Clarity on Enablement Requirement
The article provides clarity on the enablement requirement for genus claims, highlighting the need for patent holders to demonstrate sufficient disclosure to support their claims.
Demerits
Limited Scope
The article's focus on in silico experiments may be too narrow, overlooking other potential solutions to the undue experimentation problem.
Expert Commentary
The article raises important questions about the future of genus claims in light of the Supreme Court's ruling. While in silico experiments may offer a potential solution, they are not a panacea for the undue experimentation problem. Patent holders must carefully consider the enablement requirement and ensure that their claims are sufficiently supported by disclosure. The article's analysis highlights the need for ongoing dialogue between patent law practitioners, policymakers, and the scientific community to ensure that the patent system remains effective in promoting innovation.
Recommendations
- ✓ Patent holders should carefully evaluate the enablement requirement for genus claims
- ✓ Regulatory bodies should consider providing clearer guidelines on written description and enablement requirements
